Ryvu Therapeutics presents RVU602 data as Ryvu Therapeutics stock trades at EUR 3.90

Published on 10/20/2026 at 13:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RVU602 achieved complete remission in 100 percent of animals in a TNBC model. Ryvu Therapeutics stock costs EUR 3.90 on October 20, 2026.

Research evidence and market context

Ryvu presented RVU602 data on October 14, 2026, including complete remission in 100 percent of animals.
The study covered 272 cancer cell lines and used four clinically validated antibodies.
Ryvu Therapeutics stock trades at EUR 3.90 at 1:34 p.m. CEST at Lang & Schwarz on October 20, 2026.

Ryvu Therapeutics, PLSELVT00013, Illustration mit AI erstellt.

Ryvu Therapeutics (ISIN PLSELVT00013) presented preclinical RVU602 data on October 14, 2026, including complete remission in 100 percent of animals in a triple-negative breast cancer model. At Lang & Schwarz, the stock was trading at EUR 3.90 on October 20, 2026, at 1:34 p.m. CEST.

RVU602 shows broad laboratory activity

The presentation at the World ADC Congress covered an antibody-drug conjugate built around RVU602, a potential new payload class for oncology treatments. According to Stockwatch, RVU602 was tested across 272 cancer cell lines and retained activity in cells with a TOPO1 mutation, where the comparator drug lost more than 100-fold of its potency.

The company also reported activity with four clinically validated antibodies: sacituzumab, cetuximab, telisotuzumab and trastuzumab. In the key TNBC xenograft experiment, the sacituzumab-RVU602 conjugate produced complete remission in 100 percent of animals after two weekly 10 mg/kg doses, while a lower-dose schedule produced remission in 83 percent.

What does the test mean for development?

The data support a platform strategy rather than a clinical efficacy claim. The release described RVU602 as a potential third mechanistic class that could be used after or alongside ADCs based on TOPO1 or tubulin inhibitors. The same release reported more than 95 percent monomeric content in the tested conjugates and a drug-to-antibody ratio of 6 to 8, technical measures relevant to further development.

Investing.com reported on October 15, 2026, that Ryvu intends to develop RVU602 with partnering in mind while continuing its clinical programs. The next value test is therefore whether the preclinical findings lead to a partner, a development milestone or a clinical plan.

Stock context in Warsaw

Ryvu's primary listing is in Warsaw, where the stock was quoted at PLN 17.10 on October 20, 2026, according to the market snapshot. Its 52-week range was PLN 13.64 to PLN 31.90, leaving the laboratory data as a catalyst that still sits within a wide trading history.

Current Ryvu price

Ryvu Therapeutics stock was trading at EUR 3.90 at Lang & Schwarz on October 20, 2026, at 1:34 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Ryvu Therapeutics stock.